A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Starting soon · Phase 1 · Has a placebo group
Conditions studied: Obesity, Overweight
In brief
The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.
Key facts
- Study ID
- NCT07738614
- Run by
- Eli Lilly and Company
- People needed
- 56
- Starts
- 2026-07-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-07-31
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Have overweight or obesity, but are otherwise overtly healthy.
- Have a body mass index (BMI) within the range of 27.0 to 45.0 kilograms (kg)/square meter (m²), inclusive.
- Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.
You may not qualify if…
- Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have either of the following at screening
- A fasting plasma glucose concentration greater than or equal to 126 milligrams (mg)/deciliter (dL) or 7.0 millimoles (mmol)/liter (L), or
- Hemoglobin A1C (HbA1c) greater than or equal to 6.5% or 48 mmol/mole (mol).
- Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, and bipolar disorder, within the last 2 years.
- Have received a glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, or GIP/GLP-1/glucagon receptor agonist within 60 days or 5 half-lives, whichever is longer, prior to screening.
- Are in the judgment of the investigator, actively suicidal or deemed to be at significant risk for suicide.
Where it is running
- ICON Early Phase Services — San Antonio, Texas, United States
- Lilly Centre for Clinical Pharmacology — Singapore, Singapore
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.